De Vos H, Bricca G, De Keyser J, De Backer J P, Bousquet P, Vauquelin G
Department of Protein Chemistry, Vrije Universiteit Brussel, St. Genesius-Rode, Belgium.
Neuroscience. 1994 Apr;59(3):589-98. doi: 10.1016/0306-4522(94)90179-1.
Both [3H]clonidine and [3H]idazoxan bind to alpha 2 adrenoceptors. The former also labels imidazoline receptors, and the latter non-adrenergic idazoxan binding sites. In order to investigate whether the imidazoline receptors and non-adrenergic idazoxan binding sites are identical, we compared the binding characteristics of [3H]clonidine and [3H]idazoxan to these sites by radioligand binding experiments on ultra-thin slices and homogenates of human striatum. A good correlation was found between the effect of different ions on the binding characteristics of [3H]clonidine and [3H]idazoxan, and the affinities of most competing drugs. However, clonidine and rilmenidine displayed a 100- and 10-fold lower affinity, respectively, for the idazoxan binding sites than for the imidazoline receptors. Autoradiography with [3H]clonidine showed that high densities of imidazoline receptors were present in the striatum, pallidum, gyrus dentatus of the hippocampus, amygdala, and substantia nigra. Moderate densities were found throughout the cerebral cortex, thalamus and several brainstem nuclei including the nucleus olivarius inferior. Low densities were seen in the cerebellum, spinal cord and pituitary gland. As for the non-adrenergic sites labelled by [3H]idazoxan, the imidazoline receptors can be found in all major brain areas examined. However, there are some striking differences between the concentrations of imidazoline receptors and non-adrenergic idazoxan binding sites in certain brain regions. To reconcile distribution and pharmacologic data, we propose that imidazoline receptors and non-adrenergic idazoxan binding sites represent different proteins or protein complexes and that at least in the nucleus reticularis lateralis and the striatum, imidazoline receptors and non-adrenergic idazoxan binding sites may be physically associated. The regional distribution of alpha 2 adrenoceptors within the human CNS was determined by quantitative autoradiography with [3H]RX821002. The highest densities of alpha 2 adrenoceptors were found in the cerebral and cerebellar cortex, and certain regions in the medulla oblongata (floor of the IV ventricle, reticular formation, hypoglossal nucleus and nucleus olivarius inferior). No alpha 2 adrenoceptors were detected in the pituitary gland. There exists no relationship between the distribution pattern of imidazoline receptors and alpha 2 adrenoceptors, indicating that these binding sites are independent from each other.
[3H]可乐定和[3H]咪唑克生均可与α2肾上腺素能受体结合。前者还可标记咪唑啉受体,后者则标记非肾上腺素能咪唑克生结合位点。为研究咪唑啉受体与非肾上腺素能咪唑克生结合位点是否相同,我们通过对人纹状体超薄切片和匀浆进行放射性配体结合实验,比较了[3H]可乐定和[3H]咪唑克生对这些位点的结合特性。结果发现,不同离子对[3H]可乐定和[3H]咪唑克生结合特性的影响,以及大多数竞争性药物的亲和力之间存在良好的相关性。然而,可乐定和利美尼定对咪唑克生结合位点的亲和力分别比对咪唑啉受体低100倍和10倍。用[3H]可乐定进行放射自显影显示,纹状体、苍白球、海马齿状回、杏仁核和黑质中存在高密度的咪唑啉受体。在整个大脑皮层、丘脑以及包括下橄榄核在内的几个脑干核中发现中等密度。在小脑、脊髓和垂体中密度较低。至于由[3H]咪唑克生标记的非肾上腺素能位点,在所有检查的主要脑区均可发现咪唑啉受体。然而,某些脑区中咪唑啉受体和非肾上腺素能咪唑克生结合位点的浓度存在一些显著差异。为协调分布和药理学数据,我们提出咪唑啉受体和非肾上腺素能咪唑克生结合位点代表不同的蛋白质或蛋白质复合物,并且至少在外侧网状核和纹状体中,咪唑啉受体和非肾上腺素能咪唑克生结合位点可能在物理上相关联。用[3H]RX821002通过定量放射自显影确定了人中枢神经系统内α2肾上腺素能受体的区域分布。在大脑和小脑皮层以及延髓的某些区域(第四脑室底部、网状结构、舌下神经核和下橄榄核)发现了最高密度的α2肾上腺素能受体。在垂体中未检测到α2肾上腺素能受体。咪唑啉受体和α2肾上腺素能受体的分布模式之间不存在关联,表明这些结合位点相互独立。